Current through 2024 Regular Session legislation effective June 6, 2024
Section 743B.425 - Prohibited restrictions on coverage of treatment for opioid or opiate withdrawal and for post-exposure prophylactic antiretroviral drugs; exceptions(1) An insurer offering a health benefit plan as defined in ORS 743B.005 may not: (a) Require prior authorization: (A) During the first 60 days of treatment, including medication therapy, prescribed for opioid or opiate withdrawal; or(B) For post-exposure prophylactic antiretroviral drugs or at least one preexposure prophylactic antiretroviral drug;(b) Restrict the reimbursement for medication therapies, preexposure prophylactic antiretroviral drugs or post-exposure prophylactic antiretroviral drugs to in-network pharmacists or pharmacies; or(c) Subject to ORS 742.008, require a deductible, copayment, coinsurance or other cost-sharing for the coverage of human immunodeficiency virus post-exposure prophylactic drugs or therapies prescribed following a possible exposure to human immunodeficiency virus.(2) This section is not subject to ORS 743A.001.(3) This section does not prohibit prior authorization for opioids or opiates prescribed for purposes other than medication therapy or treatment of opioid or opiate abuse or addiction.(4) Subsection (1)(b) of this section does not apply to a health maintenance organization as defined in ORS 750.005.Amended by 2023 Ch. 411,§ 3, eff. 1/1/2024.Amended by 2021 Ch. 365, § 5, eff. 9/25/2021, op. 1/1/2022.743B.425 was added to and made a part of the Insurance Code by legislative action but was not added to ORS chapter 743B or any series therein. See Preface to Oregon Revised Statutes for further explanation.